Focused On-demand Library for Phosphatidylinositol polyphosphate 5-phosphatase type IV

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NRR6

UPID:

INP5E_HUMAN

Alternative names:

72 kDa inositol polyphosphate 5-phosphatase; Inositol polyphosphate-5-phosphatase E; Phosphatidylinositol 4,5-bisphosphate 5-phosphatase; Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase

Alternative UPACC:

Q9NRR6; Q15734; Q6PIV5

Background:

The Phosphatidylinositol polyphosphate 5-phosphatase type IV, known by alternative names such as 72 kDa inositol polyphosphate 5-phosphatase, plays a pivotal role in lipid signaling pathways. It specifically hydrolyzes the 5-phosphate groups of various phosphatidylinositols, crucial for cellular processes. Its activity is essential for controlling ciliary growth and stability, highlighting its significance in cellular signaling and structure.

Therapeutic significance:

Linked to Joubert syndrome 1 and a disorder characterized by intellectual disability, truncal obesity, and retinal dystrophy, this protein's dysfunction underscores its potential as a therapeutic target. Understanding the role of Phosphatidylinositol polyphosphate 5-phosphatase type IV could open doors to potential therapeutic strategies for these conditions.